TLDR: Unlearn, an AI company based in San Francisco, has raised $50 million in Series C funding. The company creates digital twins of clinical trial participants, allowing pharmaceutical companies to conduct more efficient trials and bring new treatments to patients sooner. The funding round was led by Altimeter Capital and included participation from Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. Unlearn plans to use the funds to invest in its people, data, engineering capabilities, and long-term R&D initiatives.
– Unlearn has raised $50 million in Series C funding.
– The funding round was led by Altimeter Capital and included participation from Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital.
Unlearn, an AI company based in San Francisco, has secured $50 million in Series C funding. The company specializes in creating digital twins of clinical trial participants, which allow pharmaceutical companies to conduct more efficient and effective trials. The funding round was led by Altimeter Capital, with participation from Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital.
The funds raised will be used by Unlearn to advance its artificial intelligence technology, with the goal of eliminating trial and error in medicine. This will involve investing in its team, data, engineering capabilities, and long-term research and development initiatives.
Unlearn’s AI technology is designed to empower the clinical trials of pharmaceutical companies, enabling them to achieve full enrollment faster and bring new treatments to patients more quickly. The company’s AI models generate individual digital twins for each trial participant before they are randomly assigned to the experimental or control group. These digital twins forecast the health outcomes of the participants under placebo, regardless of their actual assignment.
By utilizing digital twins and conducting highly powered clinical trials with smaller control groups, Unlearn is able to reduce the time it takes to bring new drugs and therapies to market. This has the potential to significantly improve health outcomes for patients.
Unlearn’s methods using participants’ digital twins are validated by the European Medicines Agency and align with current FDA guidance. The company aims to expand its capabilities into more therapeutic areas and build awareness of the value of digital twin technology with the funding it has raised.
Overall, the recent funding round will support Unlearn in its mission to advance the field of AI in medicine and revolutionize the way clinical trials are conducted.
